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OBJECTIVES: To estimate the costs and consequences of long-
term antiviral treatment options on mortality, morbidity and
associated costs in nucleoside-naïve CHB patients in Belgium and
compare effects between antiviral (AV) treatments with low
(entecavir; ETV) versus high probability of resistance (lamivu-
dine; LVD). METHODS: A decision-tree model simulated mor-
bidity, mortality and cost for a cohort of 1000 nucleoside-naïve
CHB eAg-negative patients under three scenarios: no treatment,
ETV 0,5 mg, LVD 100 mg. Morbidity was measured as the esti-
mated number of compensated cirrhosis, decompensated cirrho-
sis, and hepatocellular carcinoma (HCC) predicted to occur
depending on viral load (VL) levels. Life expectancy impact was
estimated using the DEALE method and life tables. Efﬁcacy data
were from published trials. Baseline VL was used as proxy to
model no treatment option. Relative-risk estimations were
derived from the R.E.V.E.A.L.-HBV Study. Direct medical costs
include management cost of liver complications. Annual costs of
liver complications were estimated from IMS hospital data.
Numbers of liver complications, Life Years Lost (LYL) and costs
were estimated over a 10-year time period. The Belgian health
care payer perspective was applied. Costs and beneﬁts were
discounted as per Belgian guidelines. RESULTS: If untreated, 329
and 163 patients are predicted to develop cirrhosis and HCC
within 10 years, respectively. Mortality due to liver complica-
tions and associated lifetime costs are estimated at approximately
5.25LYL and €60,767, respectively. If patients are started on
ETV, morbidity is reduced to 38 cirrhotic and 13 HCC events,
mortality to 0.40LYL, and costs to €6,951. If started on LVD,
outcomes are 107 cirrhotic and 47 HCC events, 1.47LYL and
lifetime costs of €19,829. CONCLUSIONS: Morbidity, mortality
and costs are higher if CHB eAg-negative patients remain
untreated. Treatment with antiviral therapy will have a major
effect on these outcomes, especially if entecavir 0,5 mg, an anti-
viral with very low probability of resistance, is used.
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OBJECTIVES: The aim of the study is to compare the cost-
effectiveness of itraconazole oral solution (400 mg/day) with ﬂu-
conazole (400 mg/day) in the primary prophylaxis of invasive
fungal infections (IFI) in patients underwent allogeneic bone
marrow transplantation (BMT) in Turkish setting. METHODS:
Model: Decision tree modeling is used in the analysis of cost-
effectiveness of options. The time horizon considered in the
model is 250 days. The study has been performed from the health
care payer perspective. Patient group: Patients who underwent
allogeneic BMT over 13 years old. Data sources: The clinical
data are acquired from published clinical studies. Resource use
data are based on expert panel. Prices of medications, institu-
tional discount rates and other costs related to the treatment
obtained from Ministry of Health Drug Price List, Price List of
Social Security Institution Health Implementation Guideline
Appendix 2/D, 8 and 9. Clinical and economic outcomes: The
clinical outcome measure is the life year gained. The model takes
all direct costs into consideration, i.e. costs of antifungal treat-
ment, hospitalization and costs related with the diagnosis and
treatment of IFIs. Because the time horizon of the model is
shorter than one year, costs are not discounted. The result is
presented as additional cost per additional life year gained.
RESULTS: Life expectancy values are 0.50 and 0.48 years for
itraconazole and ﬂuconazole, respectively. Therefore life-years
gained with itraconazole is 0.02 years. Total costs are €63,000
and €112,000 for itraconazole and ﬂuconazole, respectively.
€49,000 is saved and 0.02 life-years is gained with itraconazole
prophylaxis. Incremental cost-effectiveness ratio is calculated as
(-€2,430,000)/life year gained for itraconazole. One-way sensi-
tivity analyses proved that the results of the study are strong.
CONCLUSIONS: Itraconazole dominates ﬂuconazole with
regards to cost-effectiveness in the primary prophylaxis of IFIs in
allogeneic bone marrow transplant patients, i.e. better clinical
outcome with lower cost.
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OBJECTIVES: In long-term studies, achieving sustained viro-
logic response (SVR) after hepatitis C treatment is associated
with reduced progression to advanced liver disease. This study
aims to assess if SVR status is associated with short-term health
care utilization beneﬁts in the European Union. METHODS: A
retrospective chart review of chronic hepatitis C patients who
received peginterferon plus ribavirin (PR) therapy was conducted
in the UK, Germany, France, Italy, and Spain. Descriptive analy-
ses reported standardized annual rates of hospitalizations,
emergency/accident visits (EA), family physician/general practi-
tioner visits (GP), specialist visits (SP), and having 5 clinical
tests (TESTS). Logistic regression models were applied to assess
the impact of SVR on aforementioned outcomes. RESULTS: A
total of 165 physicians collected data for 615 patients (baseline
data: mean age 43.7 years, 33% female, 90% Caucasian, 85%
genotype-1, 26% viral load >1,000,000 IU/mL, 25% prior treat-
ment failure [TF]). PR was administered for a median of 9.1
months (interquartile range: 5.3–11.9); median post-treatment
follow-up was 6.0 months (interquartile range: 2.0–10.0). A total
of 54% of patients achieved SVR. Compared with non-SVR
patients, SVR patients had signiﬁcantly fewer annual hospital-
izations (0.3 versus 1; p < 0.05) with shorter hospital stays
(6.5 versus 8.0 days), signiﬁcantly fewer annual EA (0.7 versus
1.3, p < 0.05), and comparable GP, SP, and TESTS one year
after treatment. When controlling for confounding factors (age,
weight, gender, genotype, time between diagnosis and treat-
ment initiation, alcohol intake, past intravenous drug use, pre-
treatment liver biopsy, steatosis, pre-viral RNA, and TF status),
SVR remained associated with signiﬁcantly less risk for hospital-
ization (OR = 0.499, 95% CI = 0.277–0.899) and EA (OR =
0.52, 95% CI = 0.30–0.89). Similar results were found in the
genotype-1 patients. CONCLUSIONS: Patients who achieve
SVR have a signiﬁcantly lower risk of hospitalization and emer-
gency visits than non-SVR patients one year after PR therapy.
This analysis conﬁrms short-term health care utilization beneﬁts
of achieving SVR with hepatitis C treatment.
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